|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:ALK-GPNMB (FusionGDB2 ID:HG238TG10457) |
Fusion Gene Summary for ALK-GPNMB |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: ALK-GPNMB | Fusion gene ID: hg238tg10457 | Hgene | Tgene | Gene symbol | ALK | GPNMB | Gene ID | 238 | 10457 |
| Gene name | ALK receptor tyrosine kinase | glycoprotein nmb | |
| Synonyms | CD246|NBLST3 | HGFIN|NMB|PLCA3 | |
| Cytomap | ('ALK')('GPNMB') 2p23.2-p23.1 | 7p15.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | ALK tyrosine kinase receptorCD246 antigenanaplastic lymphoma receptor tyrosine kinasemutant anaplastic lymphoma kinase | transmembrane glycoprotein NMBglycoprotein (transmembrane) nmbglycoprotein nmb-like proteinglycoprotein nonmetastatic melanoma protein Bhematopoietic growth factor inducible neurokinin-1hematopoietic growth factor inducible neurokinin-1 typeosteoact | |
| Modification date | 20200329 | 20200315 | |
| UniProtAcc | Q9UM73 | . | |
| Ensembl transtripts involved in fusion gene | ENST00000389048, ENST00000431873, ENST00000498037, | ||
| Fusion gene scores | * DoF score | 10 X 13 X 4=520 | 7 X 8 X 4=224 |
| # samples | 10 | 7 | |
| ** MAII score | log2(10/520*10)=-2.37851162325373 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(7/224*10)=-1.67807190511264 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: ALK [Title/Abstract] AND GPNMB [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | ALK(29796807)-GPNMB(23311636), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | ALK | GO:0016310 | phosphorylation | 9174053 |
| Hgene | ALK | GO:0046777 | protein autophosphorylation | 9174053 |
| Tgene | GPNMB | GO:0001818 | negative regulation of cytokine production | 19350579 |
| Tgene | GPNMB | GO:0001934 | positive regulation of protein phosphorylation | 22891158 |
| Tgene | GPNMB | GO:0030335 | positive regulation of cell migration | 20711474 |
| Tgene | GPNMB | GO:0031954 | positive regulation of protein autophosphorylation | 19350579 |
| Tgene | GPNMB | GO:0034103 | regulation of tissue remodeling | 25010402 |
| Tgene | GPNMB | GO:0042130 | negative regulation of T cell proliferation | 19350579 |
| Tgene | GPNMB | GO:2000134 | negative regulation of G1/S transition of mitotic cell cycle | 19350579 |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS5.0 | N/A | FN066871 | ALK | chr2 | 29796807 | - | GPNMB | chr7 | 23311636 | - |
Top |
Fusion Gene ORF analysis for ALK-GPNMB |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-intron | ENST00000389048 | ENST00000258733 | ALK | chr2 | 29796807 | - | GPNMB | chr7 | 23311636 | - |
| intron-intron | ENST00000389048 | ENST00000381990 | ALK | chr2 | 29796807 | - | GPNMB | chr7 | 23311636 | - |
| intron-intron | ENST00000389048 | ENST00000409458 | ALK | chr2 | 29796807 | - | GPNMB | chr7 | 23311636 | - |
| intron-intron | ENST00000389048 | ENST00000453162 | ALK | chr2 | 29796807 | - | GPNMB | chr7 | 23311636 | - |
| intron-intron | ENST00000389048 | ENST00000478451 | ALK | chr2 | 29796807 | - | GPNMB | chr7 | 23311636 | - |
| intron-intron | ENST00000389048 | ENST00000539136 | ALK | chr2 | 29796807 | - | GPNMB | chr7 | 23311636 | - |
| intron-intron | ENST00000431873 | ENST00000258733 | ALK | chr2 | 29796807 | - | GPNMB | chr7 | 23311636 | - |
| intron-intron | ENST00000431873 | ENST00000381990 | ALK | chr2 | 29796807 | - | GPNMB | chr7 | 23311636 | - |
| intron-intron | ENST00000431873 | ENST00000409458 | ALK | chr2 | 29796807 | - | GPNMB | chr7 | 23311636 | - |
| intron-intron | ENST00000431873 | ENST00000453162 | ALK | chr2 | 29796807 | - | GPNMB | chr7 | 23311636 | - |
| intron-intron | ENST00000431873 | ENST00000478451 | ALK | chr2 | 29796807 | - | GPNMB | chr7 | 23311636 | - |
| intron-intron | ENST00000431873 | ENST00000539136 | ALK | chr2 | 29796807 | - | GPNMB | chr7 | 23311636 | - |
| intron-intron | ENST00000498037 | ENST00000258733 | ALK | chr2 | 29796807 | - | GPNMB | chr7 | 23311636 | - |
| intron-intron | ENST00000498037 | ENST00000381990 | ALK | chr2 | 29796807 | - | GPNMB | chr7 | 23311636 | - |
| intron-intron | ENST00000498037 | ENST00000409458 | ALK | chr2 | 29796807 | - | GPNMB | chr7 | 23311636 | - |
| intron-intron | ENST00000498037 | ENST00000453162 | ALK | chr2 | 29796807 | - | GPNMB | chr7 | 23311636 | - |
| intron-intron | ENST00000498037 | ENST00000478451 | ALK | chr2 | 29796807 | - | GPNMB | chr7 | 23311636 | - |
| intron-intron | ENST00000498037 | ENST00000539136 | ALK | chr2 | 29796807 | - | GPNMB | chr7 | 23311636 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for ALK-GPNMB |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Top |
Fusion Protein Features for ALK-GPNMB |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:29796807/:23311636) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| ALK | . |
| FUNCTION: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. Thinness gene involved in the resistance to weight gain: in hypothalamic neurons, controls energy expenditure acting as a negative regulator of white adipose tissue lipolysis and sympathetic tone to fine-tune energy homeostasis (By similarity). {ECO:0000250|UniProtKB:P97793, ECO:0000269|PubMed:11121404, ECO:0000269|PubMed:11278720, ECO:0000269|PubMed:11387242, ECO:0000269|PubMed:11809760, ECO:0000269|PubMed:12107166, ECO:0000269|PubMed:12122009, ECO:0000269|PubMed:15226403, ECO:0000269|PubMed:15908427, ECO:0000269|PubMed:16317043, ECO:0000269|PubMed:16878150, ECO:0000269|PubMed:17274988}. | FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for ALK-GPNMB |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for ALK-GPNMB |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for ALK-GPNMB |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | ALK | Q9UM73 | DB08865 | Crizotinib | Inhibitor | Small molecule | Approved |
| Hgene | ALK | Q9UM73 | DB09063 | Ceritinib | Antagonist | Small molecule | Approved |
| Hgene | ALK | Q9UM73 | DB11363 | Alectinib | Inhibitor | Small molecule | Approved|Investigational |
| Hgene | ALK | Q9UM73 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
| Hgene | ALK | Q9UM73 | DB12130 | Lorlatinib | Inhibitor | Small molecule | Approved|Investigational |
| Hgene | ALK | Q9UM73 | DB12141 | Gilteritinib | Inhibitor | Small molecule | Approved|Investigational |
| Hgene | ALK | Q9UM73 | DB12267 | Brigatinib | Inhibitor | Small molecule | Approved|Investigational |
Top |
Related Diseases for ALK-GPNMB |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | ALK | C0007131 | Non-Small Cell Lung Carcinoma | 28 | CGI;CTD_human |
| Hgene | ALK | C0027819 | Neuroblastoma | 13 | CGI;CTD_human;ORPHANET |
| Hgene | ALK | C0152013 | Adenocarcinoma of lung (disorder) | 8 | CGI;CTD_human |
| Hgene | ALK | C2751681 | NEUROBLASTOMA, SUSCEPTIBILITY TO, 3 | 8 | CLINGEN;UNIPROT |
| Hgene | ALK | C0206180 | Ki-1+ Anaplastic Large Cell Lymphoma | 6 | CGI;CTD_human |
| Hgene | ALK | C0334121 | Inflammatory Myofibroblastic Tumor | 4 | CGI;CTD_human;ORPHANET |
| Hgene | ALK | C0018199 | Granuloma, Plasma Cell | 3 | CTD_human |
| Hgene | ALK | C0007621 | Neoplastic Cell Transformation | 2 | CTD_human |
| Hgene | ALK | C0027627 | Neoplasm Metastasis | 2 | CTD_human |
| Hgene | ALK | C0238463 | Papillary thyroid carcinoma | 2 | ORPHANET |
| Hgene | ALK | C0001973 | Alcoholic Intoxication, Chronic | 1 | PSYGENET |
| Hgene | ALK | C0006118 | Brain Neoplasms | 1 | CGI;CTD_human |
| Hgene | ALK | C0006142 | Malignant neoplasm of breast | 1 | CTD_human |
| Hgene | ALK | C0007134 | Renal Cell Carcinoma | 1 | CTD_human |
| Hgene | ALK | C0011570 | Mental Depression | 1 | PSYGENET |
| Hgene | ALK | C0011581 | Depressive disorder | 1 | PSYGENET |
| Hgene | ALK | C0027643 | Neoplasm Recurrence, Local | 1 | CTD_human |
| Hgene | ALK | C0036341 | Schizophrenia | 1 | PSYGENET |
| Hgene | ALK | C0079744 | Diffuse Large B-Cell Lymphoma | 1 | CTD_human |
| Hgene | ALK | C0085269 | Plasma Cell Granuloma, Pulmonary | 1 | CTD_human |
| Hgene | ALK | C0153633 | Malignant neoplasm of brain | 1 | CGI;CTD_human |
| Hgene | ALK | C0278601 | Inflammatory Breast Carcinoma | 1 | CTD_human |
| Hgene | ALK | C0279702 | Conventional (Clear Cell) Renal Cell Carcinoma | 1 | CTD_human |
| Hgene | ALK | C0496899 | Benign neoplasm of brain, unspecified | 1 | CTD_human |
| Hgene | ALK | C0678222 | Breast Carcinoma | 1 | CTD_human |
| Hgene | ALK | C0750974 | Brain Tumor, Primary | 1 | CTD_human |
| Hgene | ALK | C0750977 | Recurrent Brain Neoplasm | 1 | CTD_human |
| Hgene | ALK | C0750979 | Primary malignant neoplasm of brain | 1 | CTD_human |
| Hgene | ALK | C1257931 | Mammary Neoplasms, Human | 1 | CTD_human |
| Hgene | ALK | C1266042 | Chromophobe Renal Cell Carcinoma | 1 | CTD_human |
| Hgene | ALK | C1266043 | Sarcomatoid Renal Cell Carcinoma | 1 | CTD_human |
| Hgene | ALK | C1266044 | Collecting Duct Carcinoma of the Kidney | 1 | CTD_human |
| Hgene | ALK | C1306837 | Papillary Renal Cell Carcinoma | 1 | CTD_human |
| Hgene | ALK | C1332079 | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | ORPHANET |
| Hgene | ALK | C1458155 | Mammary Neoplasms | 1 | CTD_human |
| Hgene | ALK | C1527390 | Neoplasms, Intracranial | 1 | CTD_human |
| Hgene | ALK | C2931189 | Neural crest tumor | 1 | ORPHANET |
| Hgene | ALK | C3899155 | hereditary neuroblastoma | 1 | GENOMICS_ENGLAND |
| Hgene | ALK | C4704874 | Mammary Carcinoma, Human | 1 | CTD_human |
| Tgene | C0009402 | Colorectal Carcinoma | 2 | CTD_human | |
| Tgene | C0009404 | Colorectal Neoplasms | 2 | CTD_human | |
| Tgene | C0006142 | Malignant neoplasm of breast | 1 | CTD_human;UNIPROT | |
| Tgene | C0022660 | Kidney Failure, Acute | 1 | CTD_human | |
| Tgene | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human | |
| Tgene | C0162557 | Liver Failure, Acute | 1 | CTD_human | |
| Tgene | C0678222 | Breast Carcinoma | 1 | CTD_human | |
| Tgene | C1257931 | Mammary Neoplasms, Human | 1 | CTD_human | |
| Tgene | C1458155 | Mammary Neoplasms | 1 | CTD_human | |
| Tgene | C1565662 | Acute Kidney Insufficiency | 1 | CTD_human | |
| Tgene | C2609414 | Acute kidney injury | 1 | CTD_human | |
| Tgene | C4554421 | AMYLOIDOSIS, PRIMARY LOCALIZED CUTANEOUS, 3 | 1 | GENOMICS_ENGLAND;ORPHANET | |
| Tgene | C4554601 | Amyloidosis cutis dyschromia | 1 | ORPHANET | |
| Tgene | C4704874 | Mammary Carcinoma, Human | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies